Endometrial Cancer Biomarker Changes Following Exposure to Metformin

Summary

The investigators will explore the chemopreventive role of metformin. The purpose of this study is to determine whether, among patients with endometrial cancer, treatment with the currently approved insulin sensitizing drug metformin increases or decreases pathway activation distal to the insulin receptor in endometrial cancer tissue. This is a phase IIa study of metformin to be used to the pre-operative period of women diagnosed with endometrial cancer by comparing their endometrial biopsy specimens taken at their initial visit and after 4-6 weeks of treatment of metformin on the day of their surgical staging.

Timeline

Start

2016-08

Primary completion

2017-12

Completion

—

Outcome

Outcome not reported

Stopped: “Did not obtain Health Canda approval for drug use in reasonable time and moved onward to new trial”

Drugs

Indications